• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如果等水合和等渗条件不适用,注射用药物剂型可接受的pH值和渗透压是多少?

If Euhydric and Isotonic Do Not Work, What Are Acceptable pH and Osmolality for Parenteral Drug Dosage Forms?

作者信息

Roethlisberger Dieter, Mahler Hanns-Christian, Altenburger Ulrike, Pappenberger Astrid

机构信息

F. Hoffmann-La Roche Ltd., Pharmaceutical Development and Supplies, Pharma Technical Development Biologics EU, Basel, Switzerland.

F. Hoffmann-La Roche Ltd., Pharmaceutical Development and Supplies, Pharma Technical Development Biologics EU, Basel, Switzerland.

出版信息

J Pharm Sci. 2017 Feb;106(2):446-456. doi: 10.1016/j.xphs.2016.09.034. Epub 2016 Nov 23.

DOI:10.1016/j.xphs.2016.09.034
PMID:27889072
Abstract

Parenteral products should aim toward being isotonic and euhydric (physiological pH). Yet, due to other considerations, this goal is often not reasonable or doable. There are no clear allowable ranges related to pH and osmolality, and thus, the objective of this review was to provide a better understanding of acceptable formulation pH, buffer strength, and osmolality taking into account the administration route (i.e., intramuscular, intravenous, subcutaneous) and administration technique (i.e., bolus, push, infusion). This evaluation was based on 3 different approaches: conventional, experimental, and parametric. The conventional way of defining formulation limits was based on standard pH and osmolality ranges. Experimental determination of titratable acidity or in vitro hemolysis testing provided additional drug product information. Finally, the parametric approach was based on the calculation of theoretical values such as (1) the maximal volume of injection which cannot shift the blood's pH or its molarity out of the physiological range and (b) a dilution ratio at the injection site and by verifying that threshold values are not exceeded. The combination of all 3 approaches can support the definition of acceptable pH, buffer strength, and osmolality of formulations and thus may reduce the risk of failure during preclinical and clinical development.

摘要

注射用产品应尽量做到等渗和等水(生理pH值)。然而,出于其他考虑,这一目标往往不合理或无法实现。目前尚无关于pH值和渗透压的明确允许范围,因此,本综述的目的是在考虑给药途径(即肌肉注射、静脉注射、皮下注射)和给药技术(即推注、推注、输注)的情况下,更好地理解可接受的制剂pH值、缓冲强度和渗透压。该评估基于三种不同的方法:传统方法、实验方法和参数方法。定义制剂限度的传统方法基于标准pH值和渗透压范围。可滴定酸度的实验测定或体外溶血试验提供了更多的药品信息。最后,参数方法基于理论值的计算,如(1)不会使血液pH值或摩尔浓度超出生理范围的最大注射体积,以及(b)注射部位的稀释率,并通过验证不超过阈值。这三种方法的结合可以支持确定制剂可接受的pH值、缓冲强度和渗透压,从而可能降低临床前和临床开发过程中的失败风险。

相似文献

1
If Euhydric and Isotonic Do Not Work, What Are Acceptable pH and Osmolality for Parenteral Drug Dosage Forms?如果等水合和等渗条件不适用,注射用药物剂型可接受的pH值和渗透压是多少?
J Pharm Sci. 2017 Feb;106(2):446-456. doi: 10.1016/j.xphs.2016.09.034. Epub 2016 Nov 23.
2
Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration.评估在生理盐水、注射用无菌水和用于鞘内给药的乳酸林格氏液中配制的不同浓度甲氨蝶呤、阿糖胞苷和噻替派的渗透压和pH值。
J Oncol Pharm Pract. 2009 Mar;15(1):45-52. doi: 10.1177/1078155208096902. Epub 2008 Sep 4.
3
Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site.皮下注射药物:影响注射部位疼痛感知的因素文献综述。
Adv Ther. 2019 Nov;36(11):2986-2996. doi: 10.1007/s12325-019-01101-6. Epub 2019 Oct 5.
4
The Osmolality and Hemolysis of High-Concentration Monoclonal Antibody Formulations.高浓度单克隆抗体制剂的渗透压和溶血。
Pharm Res. 2024 Feb;41(2):281-291. doi: 10.1007/s11095-023-03650-6. Epub 2024 Jan 3.
5
Buffer solutions in drug formulation and processing: How pK values depend on temperature, pressure and ionic strength.药物制剂和加工中的缓冲溶液:pK 值如何随温度、压力和离子强度而变化。
Int J Pharm. 2019 Apr 5;560:357-364. doi: 10.1016/j.ijpharm.2019.02.019. Epub 2019 Feb 22.
6
Tolerability of hypertonic injectables.高渗注射液的耐受性。
Int J Pharm. 2015 Jul 25;490(1-2):308-15. doi: 10.1016/j.ijpharm.2015.05.069. Epub 2015 May 29.
7
Intravenous Admixture Preparation Considerations, Part 6: pH Considerations -- Applications.静脉药物混合配制的注意事项,第6部分:pH值注意事项——应用
Int J Pharm Compd. 2020 Sep-Oct;24(5):397-402.
8
Osmolality of antisense oligonucleotide parenteral formulations: Implications on counterion dissociation and recommended osmometry techniques.反义寡核苷酸肠胃外制剂的渗透压:对抗衡离子解离的影响及推荐的渗透压测定技术
Int J Pharm. 2016 Dec 30;515(1-2):788-799. doi: 10.1016/j.ijpharm.2016.10.055. Epub 2016 Oct 27.
9
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms.无菌配制基础:注射剂剂型的生物药剂学
Int J Pharm Compd. 2017 Jan-Feb;21(1):47-56.
10
Basics of Compounding: Compounding Films.配药基础:配制薄膜。
Int J Pharm Compd. 2016 Jul-Aug;20(4):298-305.

引用本文的文献

1
Enhancing Parenteral Nutrition via Supplementation with Antioxidant Lutein in Human Serum Albumin-Based Nanosuspension.通过在基于人血清白蛋白的纳米混悬液中补充抗氧化剂叶黄素来增强肠外营养
Pharmaceutics. 2025 Jul 26;17(8):971. doi: 10.3390/pharmaceutics17080971.
2
Development and Validation of In Vitro Assessment Protocol of Novel Intravenous Nanoemulsions for Parenteral Nutrition.新型肠外营养静脉纳米乳剂体外评估方案的开发与验证
Pharmaceutics. 2025 Apr 8;17(4):493. doi: 10.3390/pharmaceutics17040493.
3
Parenteral Nanoemulsion for Optimized Delivery of GL-II-73 to the Brain-Comparative In Vitro Blood-Brain Barrier and In Vivo Neuropharmacokinetic Evaluation.
用于优化GL-II-73向脑内递送的肠胃外纳米乳剂——体外血脑屏障比较及体内神经药代动力学评价
Pharmaceutics. 2025 Mar 10;17(3):354. doi: 10.3390/pharmaceutics17030354.
4
Status analysis of quality control of administered infusion solution with cytotoxic drugs.含细胞毒性药物静脉输注液的质量控制现状分析
Oncol Rev. 2025 Jan 6;18:1415677. doi: 10.3389/or.2024.1415677. eCollection 2024.
5
Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.亲水性药物、蛋白质和肽类治疗药物的长效肠胃外制剂:作用机制、挑战及治疗益处,重点关注技术
Drug Deliv Transl Res. 2025 Apr;15(4):1156-1180. doi: 10.1007/s13346-024-01747-y. Epub 2024 Dec 11.
6
Novel pH-Responsive Structural Rearrangement of Myristic Acid-Conjugated Quetiapine Nanosuspension for Enhanced Long-Acting Delivery Performance.新型 pH 响应性豆蔻酸连接喹硫平纳米混悬剂的结构重排,用于增强长效给药性能。
Adv Sci (Weinh). 2024 Oct;11(40):e2405200. doi: 10.1002/advs.202405200. Epub 2024 Sep 3.
7
Effects of arginine in therapeutic protein formulations: a decade review and perspectives.精氨酸在治疗性蛋白质制剂中的作用:十年回顾与展望
Antib Ther. 2023 Oct 12;6(4):265-276. doi: 10.1093/abt/tbad022. eCollection 2023 Oct.
8
Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review.抗菌药物的物理化学特性及静脉给药实用建议:一项系统评价
Antibiotics (Basel). 2023 Aug 19;12(8):1338. doi: 10.3390/antibiotics12081338.
9
Influence of Polymer Concentration on Drying of SPION Dispersions by Electrospinning.聚合物浓度对静电纺丝法制备的超顺磁性氧化铁纳米颗粒(SPION)分散液干燥过程的影响
Pharmaceutics. 2023 May 30;15(6):1619. doi: 10.3390/pharmaceutics15061619.
10
Honokiol-Loaded Nanoemulsion for Glioblastoma Treatment: Statistical Optimization, Physicochemical Characterization, and an In Vitro Toxicity Assay.用于胶质母细胞瘤治疗的厚朴酚纳米乳剂:统计学优化、理化特性及体外毒性测定
Pharmaceutics. 2023 Jan 29;15(2):448. doi: 10.3390/pharmaceutics15020448.